01MVP built
Early Disease
Detection System
AI-powered longitudinal disease intelligence for hospitals and clinical laboratories.
Explore EDDS →
Biotechnology, built in Ghana
Read biology
earlier.
We build systems that recognize biological signals sooner—so healthcare can move from reacting to disease toward understanding what comes before it.
Our conviction
The body already carries the blueprint.
Disease, regeneration, and hydration all leave signals. We are building the intelligence to read those patterns earlier—and the science to act on them responsibly.
Three connected frontiers
One idea. Three ways forward.
From near-term clinical intelligence to long-horizon biological research, each program begins with the same question: what can biology tell us before it is obvious?
Early Disease
02Research program
Regenerative
Medicine
Investigating whether dormant human pathways could support precise retinal regeneration.
View research →03In development
Hydration &
Electrolytes
A dissolvable electrolyte and mineral formulation designed for the Ghanaian market.
See the concept →Our flagship platform
From isolated results
to living context.
EDDS turns routine laboratory results into structured, explainable trend intelligence—helping clinicians see how a patient's biomarkers relate, change, and signal risk over time.
i
EDDS provides pattern-based observations for clinician review. It is not a diagnostic device and is currently at MVP stage.
Ingest
Lab result images enter the secure workflow.
Structure
Biomarkers, units, and flags are extracted.
Connect
Related markers are grouped and interpreted together.
Review
Clear risk context supports clinician validation.
Built for the next layer
Software first.
Software first.
Infrastructure next.
The roadmap extends from longitudinal hospital intelligence toward passive, ambient data collection—creating a foundation that future diagnostic hardware can plug into.
Pilot relationshipRichard Novati Catholic Hospital
Formal documentation and ethical review in preparation.
Müller glia / pathway reactivation
Long-horizon research
Can dormant pathways be reactivated?
Our research program investigates whether mechanisms that enable retinal regeneration in zebrafish are present—but dormant—in human cells, and whether they can be safely and precisely reawakened.
FocusRetinal regeneration via Müller glia biology
StageHypothesis & experimental framework development
ApproachSix-part in-vitro proof-of-concept with safety checkpoints
This is a research direction, not a current therapy or capability. Work proceeds through appropriate academic and research-ethics channels.
Consumer health / in development
Better hydration,
built for home.
A dissolvable capsule designed to improve electrolyte and mineral uptake when added to drinking water—developed for the realities of heat, movement, and everyday life in Ghana.
Formulation and testing in progressThe people behind the work
Built across disciplines.
Science, software, operations, privacy, and partnerships—working together from Ghana to the world.
Abraham Nelson Dimzang
Founder & CEO
Shadrack Kwasi Addo
Chief Technology Officer
Ella Peprah Boateng
Head of Administration
Francis Lomo
Partnerships & External Relations
Eugenia Addai-Hansen
Research Associate
Faith A. Smith
Diaspora Research Collaborator
Evangel Yorke Acquay
Legal & Privacy Advisor
Responsible by designProgress needs
Progress needs
guardrails.
Dimzang Labs is pre-seed, pre-revenue, and its clinical and consumer programs remain in development. Work involving patient data or experimental biology proceeds only through appropriate institutional, ethical, privacy, and regulatory pathways.
Collaborate with us
Help us read what
biology is already saying.
We welcome conversations with hospitals, researchers, clinical laboratories, technology partners, and early-stage investors.
hello@dimzanglabs.com ↗